China SFDA Vows Quick Action To Prevent Gel-Capsule Scandal Repeat
This article was originally published in PharmAsia News
China’s State FDA spread the word to local authorities to respond quickly and harshly to any reports of unsafe gel capsules found in their areas as part of a long-term monitoring system to prevent a scandal repeat.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.